Jasper Therapeutics (JSPR) Research & Development (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Research & Development of $11.4 million for Q4 2025, down 42.55% year-over-year from $19.8 million in Q4 2024, and down 21.06% quarter-over-quarter from $14.4 million in Q3 2025.
Jasper Therapeutics (JSPR) Research & Development (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Research & Development history runs 6 years deep, the most recent figure standing at $11.4 million for Q4 2025.
- In Q4 2025, Research & Development fell 42.55% year-over-year to $11.4 million; the TTM figure through Dec 2025 stood at $63.1 million (up 13.05% YoY), while the FY2025 annual figure was $63.1 million, up 13.05% from the prior year.
- Research & Development for Q4 2025 stood at $11.4 million, down from $14.4 million in the prior quarter.
- The five-year high for Research & Development was $21.2 million in Q2 2025, with the low at $842000.0 in Q4 2022.
- The 5-year median for Research & Development is $10.8 million (2024), against an average of $11.1 million.
- The sharpest annual moves came in 2021 and 2022: Research & Development jumped 4823.29% in 2021, then tumbled 90.27% in 2022.
- Jasper Therapeutics' Research & Development stood at $8.7 million in 2021, then sank by 90.27% to $842000.0 in 2022, then soared by 1543.11% to $13.8 million in 2023, then surged by 42.91% to $19.8 million in 2024, then slumped by 42.55% to $11.4 million in 2025.
- Business Quant data shows JSPR's Research & Development at $11.4 million in Q4 2025, $14.4 million in Q3 2025, and $21.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 97.90 Mn |
| 10 | Jasper Therapeutics | 20.07 Mn | 20.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.36 Mn |
| Sep 30, 2025 | 14.39 Mn |
| Jun 30, 2025 | 21.20 Mn |
| Mar 31, 2025 | 16.16 Mn |
| Dec 31, 2024 | 19.77 Mn |
| Sep 30, 2024 | 14.46 Mn |
| Jun 30, 2024 | 11.30 Mn |
| Mar 31, 2024 | 10.30 Mn |
| Dec 31, 2023 | 13.84 Mn |
| Sep 30, 2023 | 14.85 Mn |
| Jun 30, 2023 | 13.30 Mn |
| Mar 31, 2023 | 9.81 Mn |
| Dec 31, 2022 | 842,000.00 |
| Sep 30, 2022 | 9.02 Mn |
| Jun 30, 2022 | 8.14 Mn |
| Mar 31, 2022 | 8.19 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 7.19 Mn |
| Jun 30, 2021 | 5.16 Mn |
| Mar 31, 2021 | 4.42 Mn |